{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:00:41Z","timestamp":1794002441838,"version":"4.8.0"},"reference-count":33,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Rheumatoid arthritis (RA) is a representative systemic autoimmune rheumatic disease (SARD) characterized by synovial inflammation. While antinuclear antibodies (ANAs) positivity in patients with RA varies widely, the relationship between ANA patterns and clinical features remains unclear. This study aimed to evaluate the clinical significance of ANA in patients with RA. Methods: This single-center RA registry study included 814 Japanese patients after excluding those with coexisting SARDs. ANA titers and staining patterns were assessed by indirect immunofluorescence assays on HEp-2 cells. Clinical and laboratory features were analyzed, and logistic regression was used to identify risk factors for pulmonary involvement. Hierarchical clustering and statistical analyses were performed to explore associations between ANA patterns and clinical features. Results: ANA positivity was observed in 41.5% of patients, with the speckled and homogeneous patterns being the most common. ANA-positive patients exhibited significantly higher rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) positivity rates and titers, along with elevated disease activity markers, including Evaluator\u2019s Global Assessment and Swollen Joint Count. Nucleolar pattern positivity was independently associated with pulmonary complications, predominantly interstitial lung disease, and higher rates of JAK inhibitor use. Discrete-speckled pattern-positive patients exhibited high ANA titers but lower RF and ACPA levels, reflecting a distinct subset of RA. Conclusions: ANA staining patterns and titers are clinically relevant in RA, with nucleolar and discrete-speckled patterns indicating distinct clinical and pathophysiological profiles. ANA should be interpreted alongside other serological markers and clinical parameters rather than as a standalone tool. Further studies are needed to refine its clinical applicability and integration into RA management.<\/jats:p>","DOI":"10.3390\/jcm14051553","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:46:37Z","timestamp":1740545197000},"page":"1553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Significance of Antinuclear Antibodies in Patients with Rheumatoid Arthritis: From SETOUCHI-RA Registry"],"prefix":"10.3390","volume":"14","author":[{"given":"Kazuhisa","family":"Nakano","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumie","family":"Hiramatsu-Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Nagasu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Koide","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 1, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid Arthritis\u2014Common Origins, Divergent Mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","first-page":"419","article-title":"Specificity of speckled ANA patterns for autoimmune diseases including SS and SLE","volume":"12","author":"Tan","year":"1969","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","article-title":"Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases","volume":"19","author":"Satoh","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s002960000073","article-title":"Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: Implications on the presentation and long-term course of the disease","volume":"20","author":"Caspi","year":"2001","journal-title":"Rheumatol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e23362","DOI":"10.1002\/jcla.23546","article-title":"Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases","volume":"34","author":"Wei","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/acr2.11271","article-title":"Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis","volume":"3","author":"Paknikar","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Liu, F., Wang, X.Q., Zou, J.W., Li, M., Pan, C.C., and Si, Y.Q. (2024). Association between serum antinuclear antibody and rheumatoid arthritis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1358114"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e15069","DOI":"10.1111\/1756-185X.15069","article-title":"Prognosis and prognostic factors of lung cancer complications in patients with rheumatoid arthritis","volume":"27","author":"Fujita","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","article-title":"Mechanisms of lung disease development in rheumatoid arthritis","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"210011","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: Manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","first-page":"e31211","article-title":"Rheumatoid Arthritis and Associated Lung Diseases: A Comprehensive Review","volume":"14","author":"Azam","year":"2022","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e001278","DOI":"10.1136\/rmdopen-2020-001278","article-title":"Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis","volume":"6","author":"Joshua","year":"2020","journal-title":"RMD Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","article-title":"Prevalence and sociodemographic correlates of antinuclear antibodies in the United States","volume":"64","author":"Satoh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.semarthrit.2019.02.003","article-title":"Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","volume":"49","author":"Ishikawa","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/art.30084","article-title":"Pattern on the antinuclear antibody\u2013HEp-2 test is a critical parameter for discriminating antinuclear antibody\u2013positive healthy individuals and patients with autoimmune rheumatic diseases","volume":"63","author":"Mariz","year":"2011","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","first-page":"879456","article-title":"Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters","volume":"13","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.autrev.2010.09.025","article-title":"Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F","volume":"10","author":"Fritzler","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_25","first-page":"2371","article-title":"Anticentromere antibody positive patients with primary Sj\u00f6gren\u2019s syndrome have distinctive clinical and immunological characteristics","volume":"41","author":"Liu","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13075-019-2013-9","article-title":"Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease","volume":"21","author":"Hafiz","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-023-01125-6","article-title":"Role of IFN-\u03b1 in Rheumatoid Arthritis","volume":"26","author":"Lin","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17476348.2023.2176303","article-title":"Identification and management of connective tissue disease-associated interstitial lung disease: Evidence-based Japanese consensus statements","volume":"17","author":"Kuwana","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tsujii, A., Isoda, K., Yoshimura, M., Nakabayashi, A., Kim, D.-S., Tamada, T., Yamamoto, K., and Ohshima, S. (2024). Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: A retrospective nested case-control study. BMC Rheumatol., 8.","DOI":"10.1186\/s41927-024-00374-x"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103636","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis","volume":"23","author":"Nolla","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/03009742.2017.1324909","article-title":"Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sj\u00f6gren\u2019s syndrome (secondary Sj\u00f6gren\u2019s syndrome) focusing on autoimmune rheumatic diseases","volume":"47","author":"Alani","year":"2017","journal-title":"Scand. J. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:39Z","timestamp":1760028159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051553"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051553","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}